Corbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference March 2, 2018
Corbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical Model February 15, 2018
Corbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference February 14, 2018
Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference February 6, 2018
Corbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support Phase 2b Clinical Study of Lenabasum January 30, 2018
Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint January 29, 2018
Corbus Pharmaceuticals Announces Initiation of Phase 2 Study of Anabasum for Treatment of Systemic Lupus Erythematosus December 22, 2017
Corbus Pharmaceuticals Holdings, Inc. Announces Exercise of Option to Purchase Additional Shares in Public Offering November 27, 2017
